Kymera Therapeutics Presents New Preclinical Data for KT-579 Kymera Therapeutics, Inc. announced the presentation of new preclinical data for KT-579, a first-in-class, oral IRF5 degrader, …
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 single-ascending do…
In the Age of Ozempic: Accessibility and Cost The effectiveness and cost of weight loss drugs like Ozempic, Wegovy, and Mounjaro have been…
OPPO and Ballet Philippines Partnership OPPO has announced a partnership with Ballet Philippines to promote Filipino artistry, marking the…
Rates of Physician Attrition From Clinical Practice Have Risen Since 2013 A recent study found that the rate of physician attrition from c…
Navigating Complex Injury Cases Dealing with a serious injury case can be stressful and confusing, with nearly 70 percent of personal inju…
Study Claims Ozempic Lowers Biological Age Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope i…
Designing Light-Filled Living Spaces In Florida, natural light is one of the state’s most abundant resources—and homeowners are increasing…
World Treadmill Championships to Debut in 2026 The first-ever World Treadmill Championships, dubbed RUN X, will take place over 5km in 202…
New Toronto Transit Station to Open A new station serving GO Transit's Kitchener Line and UP Express is set to open in weeks. Metro…
Dracula Technologies Secures €30M in Series A Round Valence, France-based Dracula Technologies has announced the successful completion of …